Rovalpituzumab tesirine, a DLL3-targeted antibody-drug conjugate, in recurrent small-cell lung cancer: a first-in-human, first-in-class, open-label, phase 1 study

BACKGROUND: Rovalpituzumab tesirine is a first-in-class antibody-drug conjugate directed against delta-like protein 3 (DLL3), a novel target identified in tumour-initiating cells and expressed in more than 80% of patients with small-cell lung cancer. We aimed to assess the safety and activity of rov...

Description complète

Enregistré dans:
Détails bibliographiques
Publié dans:Lancet Oncol
Auteurs principaux: Rudin, Charles M, Pietanza, M Catherine, Bauer, Todd M, Ready, Neal, Morgensztern, Daniel, Glisson, Bonnie S, Byers, Lauren A, Johnson, Melissa L, Burris, Howard A, Robert, Francisco, Han, Tae H, Bheddah, Sheila, Theiss, Noah, Watson, Sky, Mathur, Deepan, Vennapusa, Bharathi, Zayed, Hany, Lally, Satwant, Strickland, Donald K, Govindan, Ramaswamy, Dylla, Scott J, Peng, Stanford L, Spigel, David R
Format: Artigo
Langue:Inglês
Publié: 2016
Sujets:
Article
Accès en ligne:https://ncbi.nlm.nih.gov/pmc/articles/PMC5481162/
https://ncbi.nlm.nih.gov/pubmed/27932068
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1016/S1470-2045(16)30565-4
Tags: Ajouter un tag
Pas de tags, Soyez le premier à ajouter un tag!

Documents similaires